Day One Entered into an Exclusive License Agreement and Research Collaboration with Sprint Bioscience for VRK1 Program
Shots:
- Sprint Bioscience to receive $3M up front and reimburse Sprint Bioscience for pre-clinical research and development expenses & will be eligible to receive an additional fee of ~$313M upon achievement of research, development, regulatory, and commercial outcomes along with royalties
- Day One gets an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult cancers with high unmet needs. Additionally, the collaboration expands Day One’s portfolio of targeted therapies in oncology
- Day One’s tovorafenib, an oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor & pipeline incl. pimasertib, oral, highly-selective small molecule inhibitor of MEK-1/-2
Ref: Globenewswire | Image: Day One
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
